Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer to Use Ingenuity Systems' Software in Rx Programs

NEW YORK (GenomeWeb News) – Pfizer Pharmaceuticals will use Ingenuity Systems’ bioinformatics software under a multi-year agreement, Ingenuity said today.
 
Under the agreement, Pfizer will integrate the Ingenuity Pathway Analysis software and related content from Ingenuity’s biological and chemical knowledgebase with other informatics solutions that Pfizer uses throughout its organization, Ingenuity said.
 
Ingenuity CEO Jake Leschly said that the company also has tailored “a suite of powerful capabilities” specifically for Pfizer.
 
The IPA software enables scientists to model and analyze biological and chemical systems, and its search functions give users access to information about genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways.
 
Financial terms of the agreement were not released.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.